在急性髓性白血病中B7-H3:从预后生物标志物到免疫治疗点

Xiao Tan1, Xiangyu Zhao

  • 1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.

PubMed
概括

B7-H3在急性髓性白血病 (AML) 中过度表达,促进瘤生长和免疫逃避. 向B7-H3为AML提供了一个有前途的治疗策略,同时作为预后生物标志物和治疗目标.